2022
Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents
Hood KK, Garcia‐Willingham N, Hanes S, Tanenbaum ML, Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell F, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R, Consortium T. Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes Obesity And Metabolism 2022, 24: 2309-2318. PMID: 35837984, PMCID: PMC9804666, DOI: 10.1111/dom.14815.Peer-Reviewed Original Research
2020
Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes
Nimri R, Battelino T, Laffel LM, Slover RH, Schatz D, Weinzimer SA, Dovc K, Danne T, Phillip M. Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nature Medicine 2020, 26: 1380-1384. PMID: 32908282, DOI: 10.1038/s41591-020-1045-7.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin dose adjustmentPhysician armDose adjustmentAcademic diabetes centerInsulin pump settingsPrimary efficacy measureSevere adverse eventsTarget glucose rangeInsulin pump therapyNon-inferiority trialArtificial intelligence-based decision support systemAdverse eventsInsulin titrationDiabetes CenterEfficacy measuresPump therapyPercentage of timePercentage of readingsGlucose levelsSix monthsContinuous glucose monitoring devicesDiabetesInsulin pumpGlucose monitoring devices
2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer S, Bonnemaire M, Sawhney S, Stewart J, Wang S, de Cassia Castro R, Garg S. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 471-477. PMID: 31335194, PMCID: PMC6708262, DOI: 10.1089/dia.2019.0157.Peer-Reviewed Original ResearchConceptsSotagliflozin 200Insulin therapyHypoglycemia eventsRate of hypoglycemiaType 1 diabetesLevel 2 hypoglycemiaLower ratesImportant hypoglycemiaHypoglycemia ratesWeek 52Adult patientsGlycemic controlHypoglycemic eventsHypoglycemic rateClinical trialsInsulin treatmentPlaceboSotagliflozinHypoglycemiaType 1Phase 3PatientsTherapyWeeksAdults
2018
Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management
Adams RN, Tanenbaum ML, Hanes SJ, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management. Diabetes Technology & Therapeutics 2018, 20: 648-653. PMID: 30239219, DOI: 10.1089/dia.2018.0174.Peer-Reviewed Original ResearchConceptsManagement distressHuman factorsTechnology attitudesGlycemic outcomesType 1 diabetes outcomesHybrid closed-loop systemPsychosocial factorsMultisite clinical trialTrial periodDistressTrial exposureFear of hypoglycemiaDiabetes careOutpatient settingDiabetes outcomesClinical trialsType 1Insulin deliveryTrialsAttitudesOutcomesT-testRegression analysisFurther investigationAdolescents
2017
Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System
Iturralde E, Tanenbaum ML, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System. The Science Of Diabetes Self-Management And Care 2017, 43: 223-232. PMID: 28340542, PMCID: PMC7162535, DOI: 10.1177/0145721717697244.Peer-Reviewed Original ResearchConceptsType 1 diabetesHybrid closed-loop systemFirst hybrid closed-loop systemLong-term complicationsGlycemic controlClinical trialsUS FoodDrug AdministrationMethods ThirtyDiabetesLife benefitsInsulin deliveryMental burdenT1DArtificial pancreasConclusion UsersAttitudes of individualsFocus groupsPerceived benefitsIndividualsComplicationsPancreasCliniciansAdministrationTrialsGlucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2017, 19: 155-163. PMID: 28134564, PMCID: PMC5359676, DOI: 10.1089/dia.2016.0421.Peer-Reviewed Original ResearchConceptsHybrid closed-loop insulin delivery systemGlucose valuesDiabetic ketoacidosis eventsMulticenter pivotal trialStudy phaseBlood sample testingType 1 diabetesClosed-loop insulin delivery systemBlood glucose valuesHome useContinuous glucose monitoringSensor glucose valuesHCl therapyKetoacidosis eventsHybrid closed-loop systemPivotal trialsInsulin delivery systemsGlucose outcomesMedtronic MiniMedType 1Glucose monitoringInsulin deliveryAdultsStayAdolescents
2013
The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*
Buckingham B, Beck R, Ruedy K, Cheng P, Kollman C, Weinzimer S, DiMeglio L, Bremer A, Slover R, Cantwell M. The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*. Diabetes Technology & Therapeutics 2013, 15: 401-408. PMID: 23570538, PMCID: PMC3643224, DOI: 10.1089/dia.2013.0002.Peer-Reviewed Original ResearchConceptsType 1 diabetesMean glucose concentrationHybrid closed-loop controlMedian percentageHybrid closed-loop therapyType 1Sensor-augmented pump therapyPositive pancreatic autoantibodiesTrialNet Study GroupDays of diagnosisNormal glycemic controlΒ-cell functionGlucose concentrationClosed-loop therapyPancreatic autoantibodiesGlycemic controlSAP therapyPump therapyStudy groupGlucose levelsGlucose toxicityDay 2Day 3Glucose valuesTherapy